Alopecia Areata
Asthma
Chronic Urticaria
Dermatitis, Allergic Contact
Dermatitis, Atopic

Dupilumab

Dupilumab is an injectable prescription medication administered subcutaneously to treat severe and refractory forms of atopic dermatitis. The US Food and Drug Administration (FDA) approved the medication in April 2017 to treat moderate-to-severe, resistant, atopic dermatitis unresponsive to conventional therapy, including topical corticosteroids. Dupilumab is also used as a maintenance treatment for asthma and chronic rhinosinusitis with nasal polyposis in adults and children, in conjunction with other medications. Dupilumab is also now FDA-approved for prurigo nodularis and eosinophilic esophagitis. Non-FDA-approved indications include allergic contact dermatitis, hand dermatitis, chronic spontaneous urticaria, and alopecia areata. Extensive literature suggests the efficacy of dupilumab in treating conditions characterized by Th2-mediated inflammation. Clinical trials are currently in the pipeline to explore the potential of dupilumab in treating autoimmune blistering diseases, such as bullous pemphigoid. This activity describes dupilumab, including its mechanism of action, adverse event and safety profiles, eligible patient populations, and contraindications. It also highlights the interprofessional team’s role in managing patients on dupilumab treatment.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.